Tourette's syndrome

Current Topics in Behavioral Neurosciences

Volumn 1, Issue , 2009, Pages 397-410

  Müller Vahl, Kirsten R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Attention obsessive compulsive disorder; OCD; Tic; Tourette's syndrome

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; IODINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN; DRUG EFFECT; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; BRAIN; ENDOCANNABINOIDS; FEMALE; HUMANS; IODINE ISOTOPES; MALE; MIDDLE AGED; MORPHOLINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOURETTE SYNDROME; YOUNG ADULT;

EID: 79952117503     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/978-3-540-88955-7_17     Document Type: Article

References (52)

1. Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097-2102
2. Adriani W, Caprioli A, Granstrem O et al. (2003) The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 2:639-651
3. Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119-146
4. Benton AL (1945) A visual retention test for clinical use. Arch Neurol Psychol 59:273-291
5. Berding G, Müller-Vahl K, Schneider U et al. (2004) [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 55:904-915
6. Block RI, Ghoneim MM (1993) Effects of chronic marijuana use on human cognition. Psychopharmacology (Berl) 110:219-228
7. Cadogan AK, Alexander SP, Boyd EA et al. (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131-1137
8. Derogatis LR (1977) SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine
9. Derogatis LR, Lipman RS, Covi L (1973) SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 9:13-28
10. Di Marzo V, Hill MP, Bisogno T et al. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438
11. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15-21
12. Gadzicki D, Müller-Vahl KR, Heller D et al. (2004) Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet 127:97-103
13. Gerard E, Peterson BS (2003) Developmental processes and brain imaging studies in Tourette syndrome. J Psychosom Res 55:13-22
14. Gessa GL, Melis M, Muntoni AL et al. (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39-44
15. Giuffrida A, Parsons LH, Kerr TM et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363
16. Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318
17. Goetz CG, Tanner CM, Wilson RS et al. (1987) A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 37:1542-1544
18. Harcherik DF, Leckman JF, Detlor J et al. (1984) A new instrument for clinical studies of Tourette's syndrome. Am J Acad Child Psychiatry 23:153-160
19. Helmstaedter C, Durwen HF (1990) VLMT. Verbaler Lern-und Merkfähigkeitstest. Schweiz Arch Neurol Psychiatr 141:21-30
20. Hemming M, Yellowlees PM (1993) Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 7:389-391
21. Herkenham M, Lynn AB, Little MD et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936
22. Leckman JF, Towbin KE, Ort SI et al. (1988) Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF (eds) Tourette's syndrome and tic disorders. Wiley, NewYork
23. Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705-1712
24. Mantel BJ, Meyers A, Tran QY et al. (2004) Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol 14:582-589
25. Merz J, Lehrl S, Galster JV et al. (1975) MWT-B-ein Intelligenzkurztest. Psychiatr Neurol Med Psychol 27:423-428
26. Mink JM (2001) Neurobiology of basal ganglia circuit in Tourette Syndrome: faulty inhibition of unwanted motor patterns? Adv Neurol 85:113-122
27. Moss DE, Montgomery SP, Salo AA et al. (1984) Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Academic Press, New York
28. Moss DE, Manderscheid PZ, Montgomery SP et al. (1989) Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 44:1521-1525
29. Müller-Vahl KR (2002) The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother 3:899-914
30. Müller-Vahl KR (2006) Involvement of fronto-striatal pathways in Tourette syndrome with and without comorbid ADHD and OCD. Eur Arch Psychiatry Clin Neurosci 256:II19
31. Müller-Vahl KR, Kolbe H, Dengler R (1997a) Alcohol withdrawal and Tourette's syndrome. Neurology 48:1478-1479
32. Müller-Vahl KR, Kolbe H, Dengler R (1997b) Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms. Nervenarzt 68:985-989
33. Müller-Vahl KR, Kolbe H, Schneider U et al. (1998) Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand 98:502-506
34. Müller-Vahl KR, Schneider U, Kolbe H et al. (1999) Treatment of Tourette-syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry 156:395
35. 9-THC) treatment of Tourette-syndrome on neuropsychological testing. Pharmacopsychiatry 34:19-24
36. 9-THC and dopamine receptor antagonists. J Cannabis Ther 2:145-154
37. 9-Tetrahydrocannabinol (THC). Pharmacopsychiatry 35:57-61
38. 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384-388
39. 9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette-Syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459-465
40. Müller-Vahl KR, Buddensiek N, Geomelas M et al. (2008) The influence of different food and drink on tics in Tourette syndrome. Acta Paediatr 97:442-446
41. Patton GC, Coffey C, Carlin JB et al. (2002) Cannabis use and mental health in young people: cohort study. BMJ 325:1195-1198
42. Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123:425-462
43. Sandyk R, Awerbuch G (1988) Marijuana and Tourette's syndrome. J Clin Psychopharmacol 8:444-445
44. Shapiro AK, Shapiro ES, Young JG et al. (1988) Signs, symptoms, and clinical course. In: Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds) Gilles de la Tourette syndrome, 2nd edn. Raven Press, New York
45. Sieradzan KA, Fox SH, Hill M et al. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111
46. Singer HS (2000) Current issues in Tourette syndrome. Mov Disord 15:1051-1063
47. Singer HS, Wendtlandt JT (2001) Neurochemistry and synaptic neurotransmission in Tourette syndrome. Adv Neurol 85:163-178
48. Solowij N, Michie PT, Fox AM (1995) Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37:731-739
49. Strohbeck-Kühner P, Skopp G, Mattern R (2007) Fitness to drive in spite (because) of THC. Arch Kriminol 220:11-19
50. The Tourette syndrome classification study group (1993) Definitions and classification of tic disorders. Arch Neurol 50:1013-1016
51. Tzavara ET, Li DL, Moutsimilli L et al. (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry 59:508-515
52. Zimmermann P, Fimm B (1989) Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg